Fulcrum Therapeutics (FULC) AI Stock Analysis

• Market Cap: $432.37M
• Dividend Yield: N/A
• Average Volume (3M): 534.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: 3087.25%
• EPS Growth: 97.11%
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 53,979,305
• 10 Day Avg. Volume: 677,908
• 30 Day Avg. Volume: 534,851
• PEG Ratio: -0.53
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.31
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 0.95
• Enterprise Value/Gross Profit: 4.88
• Enterprise Value/Ebitda: -4.17
• 1Y Price Target: $8.14
• Price Target Upside: 3.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 65 Neutral
• Price Target: $7.50 ▼(-4.21%Downside)

Fulcrum Therapeutics' strong technical analysis and positive earnings call sentiment are balanced by concerns over valuation and financial performance. The stock shows potential due to positive momentum and advancements in clinical trials, but financial sustainability and cash reserves need improvement.

Positive Factors

Clinical Trial Progress

Fulcrum enters a catalyst-rich period with its Phase 1b PIONEER trial of pociredir in sickle cell disease, showing strong adherence and clean safety.

Investor Interest

There is growing investor interest in FULC’s oral small molecule approach, indicated by the stock's recent strength compared to market indices.

Program Success

The likelihood of success for Fulcrum Therapeutics' lead program in sickle cell disease has increased, prompting a raise in the price objective.

Negative Factors

Doctor Concerns

Doctors have consistent concerns about pociredir's safety and the need for longer-term data, which may limit Fulcrum Therapeutics' stock upside.

Safety Concerns

Key opinion leaders have safety concerns about pociredir, given the FDA hold for malignancy risk, and there is no consensus on it being the most promising asset.

Trial Eligibility

Fulcrum Therapeutics tightened eligibility criteria for their trial due to potential malignancy risk, reflecting caution over the drug's safety.

Fulcrum Therapeutics Business Overview & Revenue Model

Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Fulcrum Therapeutics generates revenue primarily through partnerships, collaborations, and the development of its proprietary drug candidates. The company's revenue model includes upfront payments, milestone payments, and royalties from strategic collaborations with larger pharmaceutical companies. These partnerships often involve joint research efforts, where Fulcrum provides its expertise in gene modulation and drug development while the partner contributes additional resources for clinical trials and commercialization. Fulcrum also aims to advance its own pipeline of drug candidates through clinical trials, seeking to bring therapies to market that could generate significant sales revenue upon regulatory approval.

Fulcrum Therapeutics Financial Statement Overview

Summary

Fulcrum Therapeutics demonstrates strong revenue stability and gross profit margin in the biotechnology industry, with a robust balance sheet featuring low leverage and high equity. However, the company faces challenges with operational profitability and cash flow sustainability due to consistent net losses. Future growth will depend on achieving operational efficiencies and leveraging its financial strength to drive profits.

Income Statement

Fulcrum Therapeutics shows a stable revenue over the TTM period with $80M, but the company is struggling with negative net income at -$510,000 and a significant negative EBIT margin of -15.58%. The company's gross profit margin is strong at 78.42%, indicating good cost control over production, but the high operating losses need addressing to improve profitability.

Balance Sheet

The balance sheet of Fulcrum Therapeutics is robust, with a high equity ratio of 94.15% and low debt-to-equity ratio of 0.04, indicating minimal reliance on debt. The company's stockholders' equity stands strong at $228.49M, providing a solid financial foundation. However, the company needs to focus on converting this equity strength into operational profitability.

Cash Flow

Fulcrum Therapeutics shows improvement in cash flow with a positive operating cash flow of $7.81M in the TTM period, turning around from previous negative cash flows. The free cash flow is also positive at $7.56M, indicating better cash management. However, the operating cash flow to net income ratio is not sustainable at 15.31 due to negative net income, which suggests future cash flow stability is uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.00M	80.00M	2.81M	6.34M	19.16M	8.82M
Gross Profit	62.74M	78.41M	2.81M	3.93M	16.65M	6.44M
EBITDA	-6.35M	-18.24M	-108.49M	-109.72M	-78.54M	-69.23M
Net Income	-510.00K	-9.72M	-97.33M	-105.62M	-78.33M	-68.44M
Balance Sheet
Total Assets	242.65M	260.72M	257.69M	226.69M	235.00M	129.58M
Cash, Cash Equivalents and Short-Term Investments	226.60M	241.02M	236.22M	202.92M	218.16M	112.91M
Total Debt	8.11M	8.63M	10.82M	13.42M	0.00	17.00K
Total Liabilities	14.16M	17.68M	22.50M	27.74M	23.46M	34.40M
Stockholders Equity	228.49M	243.03M	235.19M	198.94M	211.54M	95.18M
Cash Flow
Free Cash Flow	7.56M	-2.50M	-91.47M	-99.01M	-80.19M	-55.00M
Operating Cash Flow	7.81M	-2.22M	-90.97M	-97.05M	-78.48M	-53.66M
Investing Cash Flow	-6.67M	32.23M	-36.69M	12.41M	-129.67M	-57.14M
Financing Cash Flow	1.09M	2.75M	118.12M	84.32M	186.51M	71.13M

Fulcrum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FULC, the sentiment is Positive. The current price of 7.83 is above the 20-day moving average (MA) of 7.12, above the 50-day MA of 6.59, and above the 200-day MA of 4.34, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 66.20 is Neutral, neither overbought nor oversold. The STOCH value of 85.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FULC.

Fulcrum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	69 Neutral	$178.70M	4.57	51.41%	―	-2.19%	34.91%
FULC	65 Neutral	$432.37M	―	-0.23%	―	3087.25%	97.11%
TNGX	61 Neutral	$654.70M	―	-61.35%	―	10.10%	-7.25%
Sector *	50 Neutral	AU$2.49B	3.26	-57.47%	2.79%	36.73%	13.67%
DSGN	47 Neutral	$229.35M	―	-22.59%	―	―	26.63%
IKT	46 Neutral	$150.17M	―	-79.02%	―	-100.00%	38.72%
DMAC	42 Neutral	$157.38M	―	-67.25%	―	―	2.53%

Fulcrum Therapeutics Corporate Events

Fulcrum Therapeutics Elects New Directors at Annual Meeting

At the 2025 annual meeting held on June 26, Fulcrum Therapeutics‘ stockholders elected Katina Dorton, Robert Gould, and Kate Haviland as class III directors for a three-year term. Additionally, stockholders approved the compensation of the company’s named executive officers and decided on an annual frequency for future advisory votes on this matter. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions underscore Fulcrum’s commitment to maintaining strong governance and financial oversight, potentially enhancing stakeholder confidence.

The most recent analyst rating on (FULC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.